Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280038 | 0.85 | DGAT1 (0.33) | DGAT1KLKB1 | |
| SCHEMBL2274763 | 0.84 | DGAT1 (0.33) | DGAT1KLKB1 | |
| SCHEMBL2277514 | 0.84 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL1635721 | 0.84 | DGAT1 (0.37) | DGAT1MAPT | |
| SCHEMBL2273593 | 0.83 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL2278197 | 0.82 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL2276399 | 0.82 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL2276252 | 0.82 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL2278452 | 0.82 | DGAT1 (0.36) | DGAT1KLKB1 | |
| SCHEMBL2273709 | 0.82 | DGAT1 (0.40) | DGAT1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247595-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2247595-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106445-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK1 | DGAT1 4681/4885KLKB1 2242/4885LNPEP 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.